In addition, experimental studies verified that CYR61 was downregulated in clinical breast cancer tissues compared to matched normal tissues, and demonstrated that CYR61 can inhibit the proliferation and growth of ER-positive BRCA cells. Here, CCN1 is linked to breast carcinoma.